CellCarta

CellCarta is a leading global CRO laboratory to the biopharmaceutical industry. With CAP accreditations and CLIA certifications for specific testing methods and facilities in Canada, USA, Belgium, Australia, and China, CellCarta provides a wide range of biomarker testing services and customized solutions to world-renowned pharmaceutical companies. By integrating analytical platforms in immunology, histopathology, proteomics, and genomics, along with sample management and logistics services, CellCarta supports the entire drug development cycle from discovery to late-stage clinical trials. Visit cellcarta.com and connect with us on LinkedIn and X.

Content by CellCarta

AI Pathology Bridges the Gap to NSCLC CDx Development

By CellCarta and Imagene AI | | 2 min read

Page 1 of 1 - 1 Total Items

October 2026

Antarctica’s Blood Falls Teems With Mysterious Microbial Life

Miles away from the closest ocean, marine microbes thrive in the red ice and mud around Blood Falls, offering clues to microbial adaptation and past climate events.

View this Issue

Research Resources

Podcasts

Webinars

Videos

Infographics

eBooks

Evaluating Blood Biomarkers for Alzheimer’s Disease Staging

Explore how blood-based biomarkers perform across Alzheimer’s disease stages, including AIBL Study findings comparing p-Tau217 and other markers against amyloid-beta and tau PET reference standards.

Find better biologics faster with Stunner and the AI Developability Workcell

Learn how microvolume UV/Vis and DLS can accelerate, automate, and streamline protein developability screening while reducing sample requirements.

An image of microcentrifuge tubes arranged within colorful laboratory racks.

Choose clarity. Choose speed. Choose MyMass™

Assess protein sample purity and homogeneity in minutes with mass photometry using only nanograms of sample.

Characterizing LNP Heterogeneity With Super-Resolution Imaging

Explore how super-resolution microscopy enables particle-level characterization of lipid nanoparticle composition, cargo loading, heterogeneity, and stability, providing complementary insights for formulation development and optimization.

Products

Product News

Stellaromics Expands Pyxa Adoption as Instruments are Installed at Leading Research Institutions Across the U.S. and EuropeStellaromics, Inc., the leader in 3D

The placements follow the commercial launch of Pyxa at the Advances in Genome Biology and Technology (AGBT) meeting in February 2026 and mark the company's transition from Early Access into global commercial availability.

A monoclonal antibody surrounded by immune cells and red blood cells